Asthma and Respiratory Disorders News

ANAHEIM, Calif — Benralizumab lowered the rate of COPD exacerbations among patients with asthma and COPD after 1 year, according to a poster presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

ANAHEIM, Calif. — ChatGPT answered accurately or somewhat accurately 91% of the time when asked about 10 allergy myths, according to a study presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

ANAHEIM, Calif. — “There are a lot of interesting trends,” John J. Oppenheimer, MD, FACAAI, clinical professor at UMDNJ Rutgers, told Healio at the American College of Allergy, Asthma & Immunology 2023 Annual Scientific Meeting.

ANAHEIM, Calif. — The wildfires in Canada in May and June 2023 were associated with short-term increases in asthma reliever use, according to a poster at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

ANAHEIM, Calif. — Unfamiliarity with biologics to treat uncontrolled asthma was reported by 42% of primary care physicians, according to a poster presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

ANAHEIM, Calif. — Between 1990 and 2019, asthma prevalence has risen in the U.S., according to a poster presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

Outcomes improved for patients with severe asthma who took mepolizumab regardless of their other comorbidities, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Providers will gather in Anaheim this week under the banner of “Embracing the Evolution of Patient Care” for the American College of Allergy, Asthma & Immunology 2023 Annual Scientific Meeting.

Income-based deductibles reduced public drug costs without any effect on medication use or adherence in patients with asthma and low incomes in British Columbia, according to a study published in Annals of Allergy, Asthma & Immunology.

Tezepelumab reduced exacerbations among patients with severe, uncontrolled asthma across all seasons regardless of their specific seasonal and perennial allergies, according to a study published in Annals of Allergy, Asthma & Immunology.